Imunon Appoints James E. Dentzer to its Board of Directors
CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J. , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon , Inc.   (N asdaq : IMNN ) , a clinical-stage drug development company, announces the appointment of James E.
October 3, 2022
Imunon Reports Partial Results from Ongoing Non-human Primate Study
Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J. , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon , Inc.   (NASDAQ: IMNN ) , a clinical-stage drug development company, reports that partial results from an ongoing non-human primate study designed to examine the
October 3, 2022
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J. , Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon , Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant
September 29, 2022
IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
LAWRENCEVILLE, N.J. , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon , Inc.  (NASDAQ: IMNN ), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff , President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming
September 27, 2022
Celsion Corporation Announces Company Name Change to Imunon, Inc.
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J. , Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced a company name change to
September 19, 2022
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress
September 1, 2022